Schrodinger Inc
SDGR
Company Profile
Business description
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Contact
1540 Broadway
24th Floor
New YorkNY10036
USAT: +1 212 295-5800
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2024
Employees
787
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,316.70 | 98.30 | -1.17% |
| CAC 40 | 7,223.75 | 70.62 | -0.97% |
| DAX 40 | 19,765.06 | 204.80 | -1.03% |
| Dow JONES (US) | 42,305.20 | 37.04 | -0.09% |
| FTSE 100 | 8,034.97 | 70.35 | -0.87% |
| HKSE | 19,720.70 | 31.81 | -0.16% |
| NASDAQ | 19,236.17 | 136.60 | -0.71% |
| Nikkei 225 | 38,701.90 | 111.68 | -0.29% |
| NZX 50 Index | 12,904.11 | 149.96 | 1.18% |
| S&P 500 | 5,847.62 | 19.46 | -0.33% |
| S&P/ASX 200 | 8,067.00 | 101.20 | -1.24% |
| SSE Composite Index | 3,368.07 | 1.96 | -0.06% |